Jeffrey Ajer - Biomarin Pharmaceutical Executive Officer
| BMRN Stock | USD 77.56 0.59 0.77% |
Executive
Jeffrey Ajer is Executive Officer of Biomarin Pharmaceutical
| Age | 62 |
| Address | 770 Lindaro Street, San Rafael, CA, United States, 94901 |
| Phone | 415 506 6700 |
| Web | https://www.biomarin.com |
Jeffrey Ajer Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jeffrey Ajer against Biomarin Pharmaceutical stock is an integral part of due diligence when investing in Biomarin Pharmaceutical. Jeffrey Ajer insider activity provides valuable insight into whether Biomarin Pharmaceutical is net buyers or sellers over its current business cycle. Note, Biomarin Pharmaceutical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Biomarin Pharmaceutical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jeffrey Ajer over two weeks ago Disposition of 5000 shares by Jeffrey Ajer of Biomarin Pharmaceutical at 82.91 subject to Rule 16b-3 |
Biomarin Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0177 % which means that it generated a profit of $0.0177 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0422 %, meaning that it created $0.0422 on every $100 dollars invested by stockholders. Biomarin Pharmaceutical's management efficiency ratios could be used to measure how well Biomarin Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of May 2024, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.03. At this time, Biomarin Pharmaceutical's Return On Tangible Assets are very stable compared to the past year. As of the 20th of May 2024, Fixed Asset Turnover is likely to grow to 2.28, while Non Currrent Assets Other are likely to drop about 72.7 M.Similar Executives
| Found 13 records | EXECUTIVE Age | ||
| William White | Walmart | N/A | |
| Gideon Blumenthal | Merck Company | N/A | |
| Ruisheng Sheng | Ping An Insurance | 53 | |
| Itzchak Angel | MIRA Pharmaceuticals Common | N/A | |
| Matthew Miner | Walmart | N/A | |
| Peter Dannenbaum | Merck Company | N/A | |
| Michael Guptan | Walmart | N/A | |
| Chirfi Guindo | Merck Company | 58 | |
| Dalton III | Merck Company | 57 | |
| Yonglin Xie | Ping An Insurance | 55 | |
| Stephanie Wissink | Walmart | N/A | |
| Joerg Koglin | Merck Company | N/A | |
| Allyson Park | Walmart | N/A | |
Management Performance
| Return On Equity | 0.0422 | ||||
| Return On Asset | 0.0177 |
Biomarin Pharmaceutical Leadership Team
Elected by the shareholders, the Biomarin Pharmaceutical's board of directors comprises two types of representatives: Biomarin Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biomarin. The board's role is to monitor Biomarin Pharmaceutical's management team and ensure that shareholders' interests are well served. Biomarin Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biomarin Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Traci McCarty, Group Relations | ||
| Jonathan Day, Executive Science | ||
| George Davis, Chief VP | ||
| Marni Kottle, Executive Officer | ||
| Humaira Serajuddin, Senior Officer | ||
| Brian Mueller, Chief Accounting Officer, Group VP and Controller | ||
| Philip Scalzo, VP Officer | ||
| Erin Burkhart, Group Officer | ||
| Greg Guyer, Executive Officer | ||
| Ganesh Vedantham, Senior Development | ||
| Kevin Eggan, Chief Development | ||
| Yen Wing, Vice Science | ||
| Amy Wireman, Executive Officer | ||
| Jeffrey Ajer, Executive Officer | ||
| Alexander Hardy, CEO President | ||
| MBA MBA, Chairman CEO |
Biomarin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biomarin Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0422 | ||||
| Return On Asset | 0.0177 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 14.78 B | ||||
| Shares Outstanding | 189.88 M | ||||
| Shares Owned By Insiders | 0.83 % | ||||
| Shares Owned By Institutions | 99.17 % | ||||
| Number Of Shares Shorted | 3.91 M | ||||
| Price To Earning | 220.73 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Biomarin Stock analysis
When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.722 | Earnings Share 1.06 | Revenue Per Share 13.12 | Quarterly Revenue Growth 0.088 | Return On Assets 0.0177 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.